# MajesTEC-4 (NCT05243797)

> Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05243797
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: European Myeloma Network B.V.
- Conditions: Multiple Myeloma
- Interventions: Teclistamab; Lenalidomide
- Enrollment: 1594
- Primary outcome: Progression Free Survival (PFS)
- Primary outcome: Minimal Residual Disease (MRD)-negative Complete Response (CR)

## Commentary we found

- X threads: 21
- Podcasts: 11
- YouTube: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=majestec-4-nct05243797

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05243797", "email": "<work email>"}; the inbox owner confirms by the emailed link.